Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells

BACKGROUND: Glioblastoma (GBM) is an aggressive brain tumor with universal recurrence and poor prognosis. The recurrence is largely driven by chemoradiation resistant cancer stem cells (CSCs). Epidermal growth factor receptor (EGFR) and its mutant EGFRvIII are amplified in ~ 60% and ~ 30% of GBM pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Vengoji, Raghupathy, Macha, Muzafar A., Nimmakayala, Rama Krishna, Rachagani, Satyanarayana, Siddiqui, Jawed A., Mallya, Kavita, Gorantla, Santhi, Jain, Maneesh, Ponnusamy, Moorthy P., Batra, Surinder K., Shonka, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582495/
https://www.ncbi.nlm.nih.gov/pubmed/31215502
http://dx.doi.org/10.1186/s13046-019-1264-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582495/
https://www.ncbi.nlm.nih.gov/pubmed/31215502
http://dx.doi.org/10.1186/s13046-019-1264-2

Ejemplares similares